New Key Antidiabetic Mushonga

rakanyorwa mupepeti

Daewoong Pharmaceutical (Daewoong) yakasimbisa inovimbisa chikamu 3 chepamusoro mhedzisiro inotarisana nemhedzisiro yekurapa seEnavogliflozin monotherapy uye musanganiswa kurapa neMetformin. Daewoong's Enavogliflozin ndeye SGLT-2 inhibitor mukusimudzira kekutanga muKorea. Chirevo chekupedzisira chepamusoro chinoita kuti chitarisirwe zvakanyanya kune zvakabudirira mhedzisiro yechikamu 3 chekiriniki yekuedza iyo yekupedzisira mushumo ichaburitswa muhafu yechipiri yegore rino.

Print Friendly, PDF & Email

Muzvinafundo Kyong Soo Park weSeoul National University Hospital semuongorori anoronga uye vaongorori vakuru kubva kumasangano makumi maviri nemaviri vakapinda muchikamu chechitatu chekuyedza kiriniki yeEnavogliflozin se monotherapy (ENHANCE-A kudzidza). Chidzidzo chacho chakaitwa seyakawanda, randomized, double-blind, placebo-controlled, uye kurapa kwekusimbisa kuedza kwakaitwa nevarwere ve22 vane chirwere cheshuga chechipiri. Mhedziso yekutanga yaive yekuongorora mutsauko uripo pakati peboka reEnavogliflozin neboka replacebo mune yekutanga shanduko yeglycated hemoglobin (HbA3c). Maererano nemushumo wepamusoro, yakatanga kuonekwa kuva 160% p pamavhiki makumi maviri nemana kubva pakutungamirirwa kwechigadzirwa chekuongorora, icho chakasimbisa kukosha kwehuwandu (P-value <2). HbA1c, inova chigadzirwa chekupedzisira chehemoglobin yakabatanidzwa neglucose yeropa, chiyero chegoridhe chekuona kuoma kwechirwere cheshuga.

Pamusoro pezvo, pakanga paine chidzidzo chakanaka chakaonekwa mune chimwe chikamu chechitatu chekiriniki yekuyedzwa kwemusanganiswa kurapa kweEnavogliflozin ine metformin naDaewoong Pharmaceutical (ENHANCE-M). Ongororo yeENHANCE-M yakaitwa naProfessor Gun Ho Yoon weThe Catholic University of Korea Seoul St. Mary's Hospital semuongorori anoronga uye vaongorori vakuru kubva kumasangano makumi maviri nematatu. Muedzo uyu wakaitwa nevarwere ve3 vane Type 23 chirwere cheshuga vasina kukwana kutonga kweglucose yeropa neMetformin. Zvichienderana nemhedzisiro ine chekuita neshanduko yekutanga yeHbA200c. Boka revarwere vakapihwa panguva imwe chete Enavogliflozin neMetformin vakabudirira kuratidza kusadzikira kwaro kuboka iro rakapihwa panguva imwe chete yeDapagliflozin neMetformin. Mhedzisiro yekuchengetedza muboka rinoshandiswa neEnavogliflozin yakasimbiswa zvakare sezvo pakange pasina zviitiko zvakashata zvisingatarisirwi kana kukanganisa kwezvinodhaka kwakaitika.

Vaongorori vakati, "Chikamu chechitatu chekiriniki kuyedzwa kweEnavogliflozin monotherapy (ENHANCE-A) uye Metformin musanganiswa wekurapa (ENHANCE-M) ine huwandu hwe3 vevatori vechikamu vekuKorea vakaratidza kudzikamisa-kudzikisa shuga uye kuchengetedzeka kwemushonga. Enavogliflozin ichava sarudzo yakanakisa yekurapa kune varwere vane Type 360 chirwere cheshuga kana mhedzisiro imwe chete yakasimbiswa kubva kune mamwe marapirwo akasanganiswa.

Sezvo mhedzisiro yakakosha yakawanikwa kubva kune ese ari maviri miedzo ye monotherapy uye Metformin musanganiswa therapy, Daewoong anofara kuburitsa SGLT-2 inhibitor nyowani kekutanga muSouth Korea. Daewoong anoronga kukurumidza kunyorera kubvumidzwa kwemushonga mutsva uye kutanga kwete chete Enavogliflozin uye asi Enavogliflozin/Metformin fixed-dose-combination (FDC) mushonga panosvika 2023. Zvichakadaro, Daewoong yakanga yatobvumidzwa kuti iite chikamu-1 chidzidzo chekuongorora bioequivalence kudzidza FDC yeEnavogliflozin uye Metformin muna Ndira 2022.

"Nekubudirira kwezviyedzo zvekiriniki zvichangoburwa, tiri kutarisirwa kupa varwere veko mushonga mutsva weBest-in-Class wechirwere cheshuga munyika munguva pfupi iri kutevera," akadaro Sengho Jeon, Daewoong Pharmaceutical CEO. "Tichayedza kuburitsa mushonga wechizvarwa chinotevera uye nekubatsira avo vanorwara nechirwere cheshuga uye matambudziko, tichichengetedza kukura kwekambani."

Print Friendly, PDF & Email

Nezvomunyori

mupepeti

Mupepeti mukuru we eTurboNew ndiLinda Hohnholz. Iye anogara muTN HQ muHonolulu, Hawaii.

Leave a Comment